Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Current Liabilities (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Total Current Liabilities data on record, last reported at $51.0 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 29.09% year-over-year to $51.0 million; the TTM value through Dec 2025 reached $51.0 million, up 29.09%, while the annual FY2025 figure was $51.0 million, 29.09% up from the prior year.
  • Total Current Liabilities reached $51.0 million in Q4 2025 per CLDX's latest filing, up from $46.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $51.0 million in Q4 2025 and bottomed at $14.2 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $26.0 million, with a median of $27.0 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: soared 106.72% in 2022, then tumbled 47.76% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $16.5 million in 2021, then increased by 12.6% to $18.6 million in 2022, then soared by 67.25% to $31.1 million in 2023, then increased by 26.91% to $39.5 million in 2024, then increased by 29.09% to $51.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $51.0 million in Q4 2025, $46.5 million in Q3 2025, and $33.0 million in Q2 2025.